Gan & Lee Pharmaceuticals. (SHA:603087)

SHA:603087 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,059	902.78	2,443	2,890	3,306	2,825
Short-Term Investments	-	-	-	201.36	276.44	945.34
Trading Asset Securities	1,298	1,500	2,410	1,636	1,624	787.05
Cash & Short-Term Investments	2,357	2,403	4,853	4,728	5,206	4,557
Cash Growth	-51.91%	-50.48%	2.66%	-9.20%	14.24%	161.44%
Accounts Receivable	328.25	213.71	383.74	189.57	934.66	827.35
Other Receivables	14.35	31.89	1.63	0.99	0.16	0.96
Receivables	342.6	245.6	385.37	190.55	934.82	828.3
Inventory	1,113	1,053	860.51	648.65	651.33	493.48
Other Current Assets	88.08	89.07	76.73	97.36	77.95	80.55
Total Current Assets	3,900	3,791	6,176	5,664	6,870	5,960
Property, Plant & Equipment	3,878	3,882	3,886	3,661	2,595	2,149
Long-Term Investments	500.69	497.03	304.66	30	201.36	466.05
Other Intangible Assets	266.66	273.06	278.08	293.48	295.99	238.92
Long-Term Deferred Tax Assets	213.85	206.94	168.95	138.25	30.8	14.93
Long-Term Deferred Charges	1,052	924.91	821.97	743.19	588.87	544.27
Other Long-Term Assets	2,473	2,468	79.99	76.51	270.33	134.67
Total Assets	12,284	12,043	11,715	10,607	10,853	9,507
Accounts Payable	112.92	115.61	94.82	36.52	26.15	14.79
Accrued Expenses	167.43	184.19	192.54	190	173.04	183.07
Current Portion of Leases	-	1.33	2.18	5.69	5.07	-
Current Income Taxes Payable	11.84	1.49	1.42	1.35	106.32	53.35
Current Unearned Revenue	54.03	63.25	52.99	68.13	36.56	68.44
Other Current Liabilities	447	435.25	429.49	511.36	138.39	90.19
Total Current Liabilities	793.21	801.13	773.45	813.04	485.53	409.85
Long-Term Leases	3.06	3.31	5.45	8.33	12.17	-
Long-Term Unearned Revenue	168.83	168.92	179.63	187.63	141.98	125.77
Long-Term Deferred Tax Liabilities	4.56	12.11	-	-	36.15	31.78
Other Long-Term Liabilities	2.65	2.97	14	12.27	10.2	1.69
Total Liabilities	972.31	988.45	972.52	1,021	686.02	569.09
Common Stock	601.07	601.07	594.16	565.65	561.54	561.54
Additional Paid-In Capital	3,611	3,591	3,351	2,563	2,476	2,474
Retained Earnings	7,371	7,059	6,865	6,525	7,133	5,905
Treasury Stock	-275.64	-200.85	-71.36	-71.36	-	-
Comprehensive Income & Other	4.38	4.04	3.82	3.44	-3.44	-1.55
Total Common Equity	11,312	11,054	10,743	9,586	10,167	8,939
Minority Interest	-	-	0	-0.16	-0.16	-0.16
Shareholders' Equity	11,312	11,054	10,743	9,586	10,167	8,938
Total Liabilities & Equity	12,284	12,043	11,715	10,607	10,853	9,507
Total Debt	3.06	4.64	7.62	14.01	17.24	-
Net Cash (Debt)	2,353	2,399	4,846	4,714	5,189	4,557
Net Cash Growth	-51.93%	-50.50%	2.80%	-9.16%	13.86%	161.44%
Net Cash Per Share	4.00	4.06	8.55	8.37	9.25	8.55
Filing Date Shares Outstanding	588.53	598.96	590.05	561.54	561.54	561.54
Total Common Shares Outstanding	588.53	598.96	590.05	561.54	561.54	561.54
Working Capital	3,107	2,990	5,402	4,851	6,385	5,550
Book Value Per Share	19.22	18.46	18.21	17.07	18.11	15.92
Tangible Book Value	11,045	10,781	10,464	9,292	9,871	8,700
Tangible Book Value Per Share	18.77	18.00	17.73	16.55	17.58	15.49
Buildings	-	2,137	1,344	1,165	1,046	1,013
Machinery	-	1,601	1,443	1,237	1,263	1,171
Construction In Progress	-	1,262	2,007	2,003	874.91	410.12

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.